Clinical trial
Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With…
NCT00094861 · Swedish Orphan Biovitrum, Industry · Completed
Key facts
| NCT number | NCT00094861 |
|---|---|
| Title | Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) in the Reduction of Dysphagia in Patients Receiving Concurrent Chemoradiotherapy Followed by Consolidation Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Swedish Orphan Biovitrum, Industry |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dysphagia, Non-Small Cell Lung Cancer, Lung Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Palifermin, Placebo, Radiotherapy, Paclitaxel, Carboplatin |
| Enrollment | 100 |
| Start date | Jan 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Jan 1, 2014 |
| First posted | Oct 27, 2004 |
| Last update posted | Mar 14, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: